Localize Opioid Use Disorder (LOUD) response to increase medication access
Project Number1R01DA060183-01A1
Former Number1R01DA060183-01
Contact PI/Project LeaderJOUDREY, PAUL J Other PIs
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
PROJECT SUMMARY
Medications for opioid use disorder (MOUD) improve the health of individuals with opioid use disorder (OUD).
However, there are significant gaps in obtaining services at each step of the opioid treatment cascade.
Individual’s access to MOUD vary by community characteristics, most often characterized simply by physical
availability (e.g., drive time to treatment location), and are different based on an individual’s age, gender, and
race/ethnicity. Using geographic availability metrics alone fails to account for other barriers and facilitators of
MOUD access (e.g., insurance, stigma, access to vehicles) and thus leads to erred assessments of
community’s responsiveness to OUD treatment needs. The patient-centered access to healthcare framework
organizes individual and structural level factors impacting access into five stages including the opportunity to (i)
identify healthcare needs, and then (ii) seek, (iii) reach, (iv) obtain, and (v) use the appropriate health care
services. The overarching goal of our study is to improve receipt of opioid treatment cascade services via data-
driven tailoring and monitoring of services. The primary objective is to develop and validate a replicable and
scalable Small Area Multidimensional MOUD Access (SAMMA) suite of measures along with computing
dashboards to enable dissemination. The rationale for this proposal is that embedding a multidimensional,
patient-centered framework of MOUD access within a socio-ecological view of health should facilitate improved
understanding of community variation in the opioid treatment cascade and enable a more sophisticated
tailoring and monitoring of interventions. The primary objective will involve three specific aims: 1) create a suite
of SAMMA measures within 50 US states and the District of Columbia; 2) validate and refine the SAMMA
measures on the community level; and 3) validate and refine the SAMMA measures by exploring access within
small areas where individual level access diverges from the SAMMA measures. For Aim 1, we will engage with
governmental health agencies and key community partners to create the SAMMA measures using publicly-
available, community level data including the American Community Survey. For Aim 2, we will validate and
refine the SAMMA measures with community level Medicaid claims data, MOUD availability data, and the
Centers for Disease Control and Prevention Social Vulnerability Index. For Aim 3, we will employ a mixed-
method convergent parallel approach using multi-location surveys of people who use drugs (PWUD) to
measure bivariate and multilevel model associations of individual level access and the SAMMA measures and
conduct semi-structured interviews among PWUD who’s individual level access diverged from the SAMMA
measures. Our innovative study will be the first to integrate multiple stages of healthcare access into a
community MOUD access measure by engaging key partners during development. It has potential for high
impact actionable insights, as we will leverage data science to better localize and monitor responses for OUD
treatment by developing a replicable and scalable suite of SAMMA measures.
Public Health Relevance Statement
PROJECT NARRATIVE
The proposed research is relevant to public health because of the ongoing rise in opioid overdose deaths
across urban and rural communities and the known racial and geographic inequities in access to medications
for opioid use disorder. Increasing the receipt of and equity in services across the opioid treatment cascade to
reduce opioid harms is a priority of the National Institute on Drug Abuse. Leveraging data science to better
localize and monitor responses for OUD treatment by developing a replicable and scalable Small Area
Multidimensional suite of measures of medication access will inform organizational-, community-, and system-
level interventions to improve receipt of services across the opioid treatment cascade.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AffectAgeAmericanAreaBuprenorphineCensusesCenters for Disease Control and Prevention (U.S.)CharacteristicsClinicCollaborationsCommunitiesCommunity SurveysCountyDataData ScienceData SetDecision AnalysisDevelopmentDimensionsDistrict of ColumbiaDrug userEnvironmentEquityEthnic OriginFundingGenderGenerationsGeographyGoalsHarm ReductionHealthHealthcareIndividualInsuranceInterventionInterviewLinkLocationMeasuresMedicaidMethadoneMethodsModelingMonitorNaltrexoneNational Institute of Drug AbuseOpioidOutcomeOverdose reductionPharmaceutical PreparationsPublic HealthRaceResearchResourcesRiskRural CommunityServicesStructureSurveysSystemTechniquesTimeUS StateUnited States Health Resources and Services AdministrationUrban CommunityVariantaccess disparitiesage relatedbeneficiarycommunity partnersdashboarddimension reductiongeographic disparityhealth care availabilityhealth care serviceimprovedindexinginnovationinsightmedication for opioid use disordermultilevel analysisopioid mortalityopioid use disorderoverdose deathpatient orientedracial disparityresponseservice organizationsocial stigmasocial vulnerabilitystructural health determinants
No Sub Projects information available for 1R01DA060183-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01DA060183-01A1
Patents
No Patents information available for 1R01DA060183-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01DA060183-01A1
Clinical Studies
No Clinical Studies information available for 1R01DA060183-01A1
News and More
Related News Releases
No news release information available for 1R01DA060183-01A1
History
No Historical information available for 1R01DA060183-01A1
Similar Projects
No Similar Projects information available for 1R01DA060183-01A1